Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

Weight loss drugs, such as those containing GLP-1 agonists like Wegovy and Mounjaro, have emerged as effective tools for people struggling to lose ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...

The Medicines and Healthcare Products Regulatory Agency (MHRA) has ruled that warnings about the risk should now be added to ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...